We are live on
!
Find out more
SCM
Suvretta Capital Management Portfolio holdings
AUM
$3.92B
1-Year Est. Return
86.67%
This Fund
S&P 500
This Quarter
Est. Return
+19.42%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$1.87B
AUM Growth
-$497M
(-21%)
Cap. Flow
-$687M
Cap. Flow
% of AUM
-36.73%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
114
New
19
Increased
26
Reduced
20
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Las Vegas Sands
LVS
|
+$40.5M |
| 2 |
Global Payments
GPN
|
+$28.9M |
| 3 |
NVIDIA
NVDA
|
+$25.7M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$24.6M |
| 5 |
Zura Bio
ZURA
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$74.5M |
| 2 |
Elevance Health
ELV
|
+$70.3M |
| 3 |
Estee Lauder
EL
|
+$56.4M |
| 4 |
Colgate-Palmolive
CL
|
+$54.4M |
| 5 |
Yum! Brands
YUM
|
+$52.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.36% |
| 2 | Technology | 11.67% |
| 3 | Consumer Discretionary | 8.46% |
| 4 | Communication Services | 5.69% |
| 5 | Financials | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Spyre Therapeutics
SYRE
$9.17B
| $1.83M | 0.1% |
162,396
| – | – |
|
77
Gilead Sciences
GILD
$166B
| $1.75M | 0.09% |
22,700
| – | – |
|
78
Illumina
ILMN
$28.6B
| $1.64M | 0.09% |
8,974
| – | – |
|
79
IQVIA
IQV
$38.8B
| $1.61M | 0.09% |
7,175
| – | – |
|
80
Medtronic
MDT
$110B
| $1.54M | 0.08% |
17,460
| – | – |
|
|
81
Elevance Health
ELV
$85.4B
| $1.34M | 0.07% |
3,010
-152,311
| -98% | -$70.3M |
|
82
Stryker
SYK
$129B
| $1.33M | 0.07% |
4,360
+1,400
| +47% | +$404K |
|
83
argenx
ARGX
$55.1B
| $1.32M | 0.07% |
3,390
| – | – |
|
84
CVS Health
CVS
$122B
| $1.19M | 0.06% |
17,170
| – | – |
|
85
Cigna
CI
$74.3B
| $1.12M | 0.06% |
4,000
| – | – |
|
86
Intuitive Surgical
ISRG
$133B
| $1.05M | 0.06% |
3,070
+1,520
| +98% | +$460K |
|
87
Boston Scientific
BSX
$71.6B
| $987K | 0.05% |
18,241
| – | – |
|
88
Waters Corp
WAT
$39.6B
| $840K | 0.04% |
3,150
| – | – |
|
89
Avantor
AVTR
$9.11B
| $786K | 0.04% |
38,250
+22,850
| +148% | +$462K |
|
90
McKesson
MCK
$102B
| $782K | 0.04% |
1,830
| – | – |
|
91
DexCom
DXCM
$31.7B
| $756K | 0.04% |
5,880
| – | – |
|
92
Sarepta Therapeutics
SRPT
$1.75B
| $694K | 0.04% |
+6,058
| New | +$781K |
|
93
Agilent Technologies
A
$40.8B
| $600K | 0.03% |
4,990
| – | – |
|
94
Idexx Laboratories
IDXX
$46.4B
| $462K | 0.02% |
920
| – | – |
|
95
United Therapeutics
UTHR
$22.8B
| $300K | 0.02% |
1,360
| – | – |
|
96
Edwards Lifesciences
EW
$51.6B
| $217K | 0.01% |
+2,300
| New | +$200K |
|
97
Mettler-Toledo International
MTD
$28.6B
| $215K | 0.01% |
164
| – | – |
|
98
Charles River Laboratories
CRL
$12.5B
| $212K | 0.01% |
1,010
| – | – |
|
99
Bio-Techne
TECH
$11.3B
| $212K | 0.01% |
+2,600
| New | +$209K |
|
|
OHAAW
100
DELISTED
OPY Acquisition Corp. I Warrant
OHAAW
| $10.9K | ﹤0.01% |
72,605
| – | – |
|
Similar funds
MIM
BCP
AS
MSI
FLSM
LWCA
TFM
USCWA
Suvretta Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Suvretta Capital Management held 114 positions worth $1.87B, down 21% from $2.37B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Suvretta Capital Management withdrew a net $687M in Q2 2023, closing 14 positions and reducing 20 holdings. Its most notable exit was Estee Lauder, an estimated $56.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Suvretta Capital Management opened a new position in Las Vegas Sands worth $39.7M.
- Suvretta Capital Management's largest Q2 2023 buy was Las Vegas Sands: 685,233 shares worth $39.7M.
- Suvretta Capital Management added most to Terns Pharmaceuticals in Q2 2023, an estimated $24.6M increase.
- Suvretta Capital Management's biggest Q2 2023 reduction was UnitedHealth, cutting an estimated $74.5M.
- Suvretta Capital Management fully exited Estee Lauder in Q2 2023, selling an estimated $56.4M.
- Suvretta Capital Management's ten largest holdings make up 41% of its $1.87B portfolio in Q2 2023.
- Suvretta Capital Management opened 19 new positions and closed 14 in Q2 2023.
- Suvretta Capital Management's portfolio value fell 21% quarter-over-quarter to $1.87B.
Based on Suvretta Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.